Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) The purpose of the University of Washington targeted long acting combination antiretroviral therapy program (UWTLC-ART) is to develop one or more safe, stable, scalable and tolerable long acting antiretroviral combinations for treatment of HIV infection in collaboration with NIH program staff. Leveraging the multidisciplinary, translational expertise and research infrastructure available at the University of Washington, this strategic drug development program integrates experts in statistics and mathematics, HIV adult and pediatric clinical trials, behavioral science, regulatory affairs, scientific and executive leadersip and business management, pharmaceutical sciences including drug targeting, delivery, metabolism and pharmacokinetics, retro virology, HIV primate models, preclinical pharmacology and toxicology, and mucosal immunology. The program has established collaborative relationships with major pharmaceutical industry and other stakeholders who can provide resources essential for the strategic development plan as well as potential future partnerships for product development. The program will also be guided by an external scientific advisory board (SAB) as well as an internal advisory group. We plan to develop three unique antiretroviral drug combination compositions/formulations, following a carefully monitored timeline. The drug combination choices are based on current antiretroviral combinations with demonstrated safety and efficacy. These drugs have known relationships between drug levels and therapeutic effect. The UWTLC-ART program utilizes a demonstrated capability to produce drug combination particles that achieve therapeutic plasma drug concentrations lasting more than seven days in a primate model. After subcutaneous injection, these compositions/formulations distribute widely throughout the lymphatic system. The program's strategic development decisions will be based on the target product profile, and will progress in accord with drug development timeline milestones. These decisions will guide prioritization of program resources to facilitate achieving the program goal. The program proposes developing three drug combinations, and will use progress on milestones, external information and the SAB to prioritize TLC-ART candidates advancing to the IND enabling studies and Phase 1 clinical trial. The program has 13 sections that are designed to interact in an integrated and collaborative way to achieve the program goal. To support the drug development, the program proposes three hypothesis-driven projects that will enhance our understanding of the distribution characteristics and safety using both pharmacokinetic/ pharmacodynamics modeling and in vivo studies. While the proposed Phase 1 clinical trial will study healthy adults, the compositions and drug development plan incorporate pediatric considerations with an eye toward future pediatric use. Although ambitious, the proposed program integrates experience and expertise, including those committed by major pharmaceutical companies to assure substantial progress in developing one or more targeted long acting antiretroviral treatments.
Poor medication adherence and insufficient drug levels are the key to understanding HIV/AIDS disease progression. The Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) program integrates translational medicine projects that seek to leverage advanced knowledge and a world-class interdisciplinary team of academic, NIH and industry researchers, and complementary experts to deliver three new, safe, stable, scalable, and well-tolerated antiretroviral combination treatments for HIV infection. The innovative therapeutic program draws on 13 related topics from the behavioral, technical, medical and pharmaceutical sciences to produce drug combination dosages that improve patient adherence and maximize therapeutic benefits.
|Mu, Qingxin; Yu, Jesse; McConnachie, Lisa A et al. (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. J Drug Target 26:435-447|
|Kraft, John C; Treuting, Piper M; Ho, Rodney J Y (2018) Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. J Drug Target 26:494-504|
|McConnachie, Lisa A; Kinman, Loren M; Koehn, Josefin et al. (2018) Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. J Pharm Sci 107:1787-1790|
|Kraft, John C; McConnachie, Lisa A; Koehn, Josefin et al. (2018) Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. J Control Release 275:229-241|
|Krogstad, Emily A; Ramanathan, Renuka; Nhan, Christina et al. (2017) Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention. Biomaterials 144:1-16|
|Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78|
|Ho, Rodney J Y (2017) Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement. J Pharm Sci 106:471-476|
|Kraft, John C; McConnachie, Lisa A; Koehn, Josefin et al. (2017) Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS 31:765-770|
|Shao, Jingwei; Kraft, John C; Li, Bowen et al. (2016) Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond) 11:545-64|
|Cherry, Allison E; Haas, Brian R; Naydenov, Alipi V et al. (2016) ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. Mol Cancer Ther 15:2018-29|
Showing the most recent 10 out of 19 publications